Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executive Briefing - How to license pharmaceutical assets

This article was originally published in Scrip

Executive Summary

Licensing is not only a mainstream activity for the pharmaceutical industry but also an intensively competitive one. Big pharma companies vie for the best opportunities, pushing up the value of highly sought after products. But how are they to know what the best opportunities are? There are literally thousands of biotech and technology companies all offering 'unique, unmissable' opportunities. This means big companies have to be very selective about which products to evaluate, and this in turn means the biotech companies must ensure that their initial presentation – which may be just 10 to 15 minutes at a bio partnering meeting – is perfectly pitched to attract the audience's attention.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts